HF
ADCT icon

HRT Financial’s ADC Therapeutics ADCT Stock Holding History

HRT Financial’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,531
Closed -$110K – 3103
2025
Q3 		$110K Sell
27,531
-10,199
-27% -$32.1K ﹤0.01% 2511
2025
Q2 		$101K Buy
+37,730
New +$79.4K ﹤0.01% 2207
2025
Q1 		– Sell
-15,073
Closed -$29K – 2454
2024
Q4 		$29K Buy
+15,073
New +$39.4K ﹤0.01% 2164
2024
Q1 		– Sell
-80,086
Closed -$132K – 2213
2023
Q4 		$132K Buy
+80,086
New +$73.9K ﹤0.01% 1858
2023
Q2 		– Sell
-16,334
Closed -$31K – 2368
2023
Q1 		$31K Buy
+16,334
New +$60.3K ﹤0.01% 2154
2022
Q4 		– Sell
-22,422
Closed -$108K – 2409
2022
Q3 		$108K Buy
+22,422
New +$162K ﹤0.01% 2377

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HRT Financial's ADCT Position: Q4 2025 in Review

HRT Financial sold out of ADC Therapeutics (ADCT) in Q4 2025, closing a stake of 27,531 shares — an estimated $110K sold.

HRT Financial first reported a position in ADCT in Q3 2022 and held it in 6 quarters. The position peaked at $132K in Q4 2023. 115 funds tracked by Wall St. Rank hold ADCT as of Q4 2025.

  • HRT Financial reported no remaining ADC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 27,531 ADC Therapeutics shares in Q4 2025, an estimated $110K.
  • HRT Financial first reported a position in ADC Therapeutics in Q3 2022 and held it in 6 quarters.
  • HRT Financial's ADC Therapeutics position peaked at $132K in Q4 2023.
  • 115 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.